Idexx Laboratories Inc (IDXX) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline...
Idexx Laboratories Inc (IDXX) currently trades at a P/E ratio of 38.74 (historical range: 33.05–81.40, median: 49.54), placing it at the 6th percentile — cheap relative to its history, P/S ratio of 9.70 (range: 7.52–19.45, 21th percentile — below its historical average), EV/EBITDA of 30.88 (range: 26.06–69.22, 6th percentile).
Over the historical period (2021-09-14 to 2026-10-16), Idexx Laboratories Inc's P/E ratio has contracted by 17% over the observed period (from an average of 55.5 to 46.1).
Idexx Laboratories Inc trades well below its historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 38.74 | 49.54 | 6th | cheap relative to its history |
| P/S Ratio | 9.70 | 11.18 | 21th | below its historical average |
| EV/EBITDA | 30.88 | 38.93 | 6th | cheap relative to its history |
| FCF Yield | 2.84% | 1.70% | 96th | cheap relative to its history |
Idexx Laboratories Inc (IDXX) Valuation & P/E History
Idexx Laboratories Inc (IDXX) is a US-listed stock operating in the Healthcare sector, specifically the In Vitro & In Vivo Diagnostic Substances industry currently trading at $560.36 with a market capitalization of $44.1 billion. This page provides historical valuation analysis for IDXX based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 38.74 is below the historical median of 49.54, placing IDXX at the 6th percentile of its valuation range. The P/S ratio of 9.70 compares to a median of 11.18.
IDXX Valuation Metrics & Historical Range
The valuation table above shows Idexx Laboratories Inc's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether IDXX is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests IDXX is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Idexx Laboratories Inc.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is IDXX Overvalued or Undervalued?
Idexx Laboratories Inc trades well below its historical valuation range across most metrics. The overall valuation percentile of 11 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive IDXX is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full IDXX analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.IDXX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.